1083168-83-5Relevant articles and documents
NOVEL TRICYCLIC COMPOUNDS
-
Page/Page column 74, (2019/05/15)
This invention relates to certain novel tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors, their synthesis and their use for treating diseases. More particularly, this invention is directed to fused heterocyclic derivatives useful as
TOLL-LIKE RECEPTOR 8 (TLR8)-SPECIFIC ANTAGONISTS AND METHODS OF MAKING AND USES THEREOF
-
Page/Page column 49-50; 74, (2019/05/22)
Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.
Use of Inhibitors of the Activity or Function of PI3K
-
Paragraph 0863-0868, (2016/01/09)
The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
QUINAZOLINE DERIVATIVES AS PI3K MODULATORS
-
Page/Page column 50-51, (2013/05/09)
The invention relates to substituted quinazoline derivative of the formula (I), wherein A, X1, X2, X3, X4 and R5 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
Use of inhibitors of the activity or function of PI3K
-
Page/Page column 97; 98, (2013/07/05)
The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
MODULATORS OF CFTR
-
Page/Page column 100-101, (2009/01/20)
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.